December 1, 2017 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has entered into a binding agreement to acquire 100% stake in Be Trū Organics™, a cause driven organization specializing in holistic products for everyday health and balance in the human body with the goal to promote well-being within the mind, body, & soul.
Be Trū is a formulator, marketer, and seller of a proprietary line of hemp extract products. Their offerings, which include topicals, oral sprays and edibles, contain powerful blends of more than 75 organic botanical terpenes and sold under the company’s Be Trū Organics™, Canatrū™, and Cebatrū™ brands.
“Isodiol and Be Trū share the common goal of providing consumers with high-quality products that promote physical and mental well-being,” said Marcos Agramont, CEO of Isodiol. “This strategic partnership would further enable us to diversify our product offerings, thus generating additional revenue streams. With both companies committed to being at the forefront of product innovation, this acquisition was an easy decision for us.”
Keith Gordon, CEO of Be Trū Organics, stated, “After our first discussion with Isodiol, it was a no-brainer that this partnership would not only be beneficial to both companies, but significantly strengthen our brands to benefit customers. We look forward to scaling our business and connecting with a group of global consumers that otherwise would have been inaccessible.”
As part of this agreement, Isodiol will issue Be Trū Organics™ up to $2,000,000 USD in stock, which will be payable at closing with shares of Isodiol’s common stock, valued at the closing price. This stock will be subject to a 36-month escrow as part of this agreement and anticipated to close within 30 days.
For more information on Be Trū Organics™, please visit www.betruorganics.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
“Marcos Agramont” CEO & Director
COMPANY MEDIA :
North 6th Agency
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.